

Bitte beachten Sie: Dieses Dokument wurde automatisch erstellt und ist kein Ersatz für das Originaldokument des Herstellers.

Product Datasheet

Melanoma Marker (MART-1 + Tyrosinase + gp100)(DT101+ BC199 + T311 + HMB45), CF647 conjugate, 0.1mg/mL, Clone: [DT101 BC199 T311 HMB45], Mouse, Monoclonal BOT-BNC470704-100

| | |
|--------------------------|---|
| Artikelname | Melanoma Marker (MART-1 + Tyrosinase + gp100)(DT101+ BC199 + T311 + HMB45), CF647 conjugate, 0.1mg/mL, Clone: [DT101 BC199 T311 HMB45], Mouse, Monoclonal |
| Artikelnummer | BOT-BNC470704-100 |
| Hersteller Artikelnummer | BNC470704-100 |
| Alternativnummer | BOT-BNC470704-100-100UL |
| Hersteller | Biotium |
| Wirt | Mouse |
| Kategorie | Antikörper |
| Applikation | IHC |
| Spezies Reaktivität | Human |
| Immunogen | Recombinant hMART-1 protein (DT101 & BC199), Extract of pigmented melanoma metastases from lymph nodes (HMB45), Recombinant tyrosinase protein (T311) |
| Konjugation | CF647 |
| Produktbeschreibung | This antibody cocktail recognizes three melanoma-specific proteins, which include MART-1, Tyrosinase and gp100. MART-1 is a newly identified melanocyte differentiation antigen recognized by autologous cytotoxic T lymphocytes. Tyrosinase is one of the... |
| Klonalität | Monoclonal |

| | |
|------------------------|--|
| Konzentration | 0.1 mg/mL |
| Klon-Bezeichnung | [DT101 BC199 T311 HMB45] |
| Molekulargewicht | 20-22 kDa (doublet) (MART-1), 90-100 kDa (gp100), 70-80 kDa (Tyrosinase) |
| Puffer | PBS, 0.1% BSA, 0.05% azide |
| Quelle | Animal |
| Anwendungsbeschreibung | Higher concentration may be required for direct detection using primary antibody conjugates than for indirect detection with secondary antibody Immunohistochemistry (formalin-fixed): 0.5-1.0 ug/mL for 30 minutes at RT Staining of formalin-fixed tissues is enhanced by boiling tissue sections in 10 mM citrate buffer pH 6.0 for 10-20 minutes followed by cooling at RT for 20 minutes Optimal dilution for a specific application should be determined by user |